Atrium Therapeutics Launches With $270M for RNA Therapies Addressing Rare Cardio Conditions

When Novartis agreed to buy RNA therapies developer Avidity Biosciences last fall, the companies said the plan was to spin out Avidity’s cardiology assets into a separate, publicly traded company. That biotech has launched bearing the name Atrium Therapeutics. Atrium’s debut followed Novartis’s Friday close of its $12 billion acquisition of Avidity, which includes two […]